Bivalirudin
- TRADE NAME: Angiomax (The Medicines Company)
- INDICATIONS: Angioplasty adjunct
- CLASS: Thrombin inhibitor
- HALF-LIFE: 25 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anisindione, Dicumarol, Heparin, Reteplase, Streptokinase, Tenecteplase, Urokinase, Warfarin
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RENAL.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of bivalirudin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric